These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 37002211)

  • 1. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.
    Yang Y; Liu H; Chen Y; Xiao N; Zheng Z; Liu H; Wan J
    Cell Death Dis; 2023 Mar; 14(3):230. PubMed ID: 37002211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer.
    Yin X; Liao H; Yun H; Lin N; Li S; Xiang Y; Ma X
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):146-159. PubMed ID: 35963564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer.
    Sinoquet L; Jacot W; Quantin X; Alix-Panabières C
    Clin Chem; 2023 Jan; 69(1):23-40. PubMed ID: 36322450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives.
    Guven DC; Sahin TK; Dizdar O; Kilickap S
    Biomark Med; 2020 Oct; 14(14):1383-1392. PubMed ID: 33064030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
    Hofman P; Heeke S; Alix-Panabières C; Pantel K
    Ann Oncol; 2019 Sep; 30(9):1448-1459. PubMed ID: 31228184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.
    Brozos-Vázquez EM; Díaz-Peña R; García-González J; León-Mateos L; Mondelo-Macía P; Peña-Chilet M; López-López R
    Cancer Immunol Immunother; 2021 May; 70(5):1177-1188. PubMed ID: 33113004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
    Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
    Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
    Dhar M; Wong J; Che J; Matsumoto M; Grogan T; Elashoff D; Garon EB; Goldman JW; Sollier Christen E; Di Carlo D; Kulkarni RP
    Sci Rep; 2018 Feb; 8(1):2592. PubMed ID: 29416054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
    Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
    Li S; Zhang C; Pang G; Wang P
    Front Immunol; 2020; 11():603157. PubMed ID: 33178229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation.
    Ren J; Liu R
    Methods Mol Biol; 2023; 2695():145-163. PubMed ID: 37450117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.
    Meri-Abad M; Moreno-Manuel A; García SG; Calabuig-Fariñas S; Pérez RS; Herrero CC; Jantus-Lewintre E
    Crit Rev Oncol Hematol; 2023 Feb; 182():103891. PubMed ID: 36565893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.
    Michaelidou K; Agelaki S; Mavridis K
    Expert Rev Mol Diagn; 2020 Mar; 20(3):335-344. PubMed ID: 32000550
    [No Abstract]   [Full Text] [Related]  

  • 20. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.